SEARCH:   Advanced

Blood, 1 October 2008, Vol. 112, No. 7, pp. 2687-2693. Prepublished online as a Blood First Edition Paper on July 14, 2008; DOI 10.1182/blood-2008-03-147025. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-03-147025v1 112/7/2687    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Geisler, C. H. Articles by Elonen, E. Search for Related Content PubMed PubMed Citation Articles by Geisler, C. H. Articles by Elonen, E. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 25, 2008 Accepted June 14, 2008 Long-term progression-free survival of mantle cell lymphoma following intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A non-randomized phase-II multicenter study by the Nordic Lymphoma Group Christian H. Geisler*, Arne Kolstad, Anna Laurell, Niels S. Andersen, Lone B. Pedersen, Mats Jerkeman, Mikael Eriksson, Marie Nordstrom, Eva Kimby, Anne Marie Boesen, Outi Kuittinen, Grete F. Lauritzsen, Herman Nilsson-Ehle, Elisabeth Ralfkiaer, Mans Akerman, Mats Ehinger, Christer Sundstrom, Ruth Langholm, Jan Delabie, Marja-Liisa Karjalainen-Lindsberg, Peter Brown, and Erkki Elonen Hematology, Rigshospitalet, Copenhagen, Denmark Oncology, The Norwegian Radium Hospital, Oslo, Norway Pathology, Uppsala University Hospital, Uppsala, Sweden Oncology, Lund University Hospital, Lund, Sweden Medicine and Hematology, Karolinska Institute, Stockholm, Sweden Hematology, Aarhus University Hospital, Aarhus, Denmark Oncology, Oulu University Hospital, Oulu, Finland Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden Hematology, Helsinki University Central Hospital, Helsinki, Finland * Corresponding author; email: christian.geisler{at}rh.regionh.dk. Mantle cell lymphoma (MCL) is considered incurable. Intensive immunochemotherapy with stem-cell support has not been tested in large, prospective series. In the 2nd Nordic MCL Trial we treated 160 consecutive, untreated patients <66 years of age in a phase-II protocol with dose-intensified induction immunochemotherapy with rituximab (R) + cyclophosphamide, vincristine, doxorubicin, prednisone (maxi-CHOP)) alternating with R + high-dose cytarabine. Responders received high-dose chemotherapy with BEAM or BEAC (carmustine, etoposide, cytarabine, and melphalan/cyclophosphamide) with R-in-vivo purged autologous stem-cell support. Overall and complete response was achieved in 96 and 54% respectively. The projected 6-year overall, event-free, and progression-free survival were 70, 56 and 66%, respectively, with no relapses occurring after 5 years. Multivariate analysis showed ki-67 to be the sole independent predictor of event-free survival. The non-relapse mortality was 5%. The majority of stem cell products and patients assessed with PCR (polymerase-chain-reaction) posttransplant were negative. Compared to our historical control of the Nordic MCL1 trial, the event-free, overall and progression-free survival, the duration molecular remission and the proportion of PCR-negative stem-cell products were significantly increased (P<0.001). Conclusion: intensive immuno-chemotherapy with in-vivo purged stem-cell support, can lead to long-term progression-free survival of MCL and perhaps cure. Registered at www.isrctn.org as ISRCTN 87866680. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Y. L. Kasamon, R. J. Jones, R. A. Brodsky, E. J. Fuchs, W. Matsui, L. Luznik, J. D. Powell, A. L. Blackford, A. Goodrich, C. D. Gocke, et al. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma Ann. Onc., October 30, 2009; (2009) mdp484v1. [Abstract] [Full Text] [PDF] N. S. Andersen, L. B. Pedersen, A. Laurell, E. Elonen, A. Kolstad, A. M. Boesen, L. M. Pedersen, G. F. Lauritzsen, R. Ekanger, H. Nilsson-Ehle, et al. Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma J. Clin. Oncol., September 10, 2009; 27(26): 4365 - 4370. [Abstract] [Full Text] [PDF] A. J. Moskowitz and C. H. Moskowitz Controversies in the Treatment of Lymphoma with Autologous Transplantation Oncologist, September 1, 2009; 14(9): 921 - 929. [Abstract] [Full Text] [PDF] M. Ghielmini and E. Zucca How I treat mantle cell lymphoma Blood, August 20, 2009; 114(8): 1469 - 1476. [Abstract] [Full Text] [PDF] K. Gustafsson, B. Sander, J. Bielawski, Y. A. Hannun, and J. Flygare Potentiation of Cannabinoid-Induced Cytotoxicity in Mantle Cell Lymphoma through Modulation of Ceramide Metabolism Mol. Cancer Res., July 1, 2009; 7(7): 1086 - 1098. [Abstract] [Full Text] [PDF] C. S. Tam, R. Bassett, C. Ledesma, M. Korbling, A. Alousi, C. Hosing, P. Kebraei, R. Harrell, G. Rondon, S. A. Giralt, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma Blood, April 30, 2009; 113(18): 4144 - 4152. [Abstract] [Full Text] [PDF] Aggressive Therapy for Mantle Cell Lymphoma Journal Watch Oncology and Hematology, September 23, 2008; 2008(923): 1 - 1. [Full Text]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020